Skip to main content
Clinical Trials/NCT05725759
NCT05725759
Enrolling by Invitation
N/A

The Effects of Rehabilitation on Functional Outcomes in Patients With SOD1 ALS Treated With Tofersen

Washington University School of Medicine1 site in 1 country10 target enrollmentNovember 8, 2022

Overview

Phase
N/A
Intervention
Not specified
Conditions
Amyotrophic Lateral Sclerosis
Sponsor
Washington University School of Medicine
Enrollment
10
Locations
1
Primary Endpoint
Change from baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS)
Status
Enrolling by Invitation
Last Updated
2 years ago

Overview

Brief Summary

The primary objective of this study is to document and describe the effects of a personalized rehabilitation program for patients with SOD1 ALS participating in the tofersen expanded access program. Participants currently receiving tofersen treatment will be referred to outpatient physical and/or occupational therapy. Participants will have an initial assessment performed and an individualized rehabilitation program will be prescribed. Each participant is encouraged to follow the prescribed recommendations that will include scheduled outpatient therapy sessions, functional assessments, and/or a home-based rehabilitation program. Functional assessments will be done at a minimum of every three months.

Registry
clinicaltrials.gov
Start Date
November 8, 2022
End Date
December 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Sean E Smith

Instructor in Neurology

Washington University School of Medicine

Eligibility Criteria

Inclusion Criteria

  • Confirmed diagnosis of ALS with an SOD1 mutation
  • Current enrollment in the tofersen expanded access program
  • Age greater than 18 years
  • Medically able to participate in outpatient physical therapy and/or home-based rehabilitation, as determined by the treating health care provider

Exclusion Criteria

  • Any comorbidities or conditions that, in the opinion of the treating healthcare provider, would unacceptably increase the risk of participation in outpatient physical therapy and/or home-based rehabilitation

Outcomes

Primary Outcomes

Change from baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS)

Time Frame: 12 months

ALSFRS-R measures functional disease severity in four functional domains, bulbar function, gross motor skills, fine motor skills, and respiratory. The assessment contains 12 questions scored from 0 (no function) to 4 (full function), with a total possible score of 48, which will indicate the highest level of function.

Secondary Outcomes

  • 1. Change from baseline in Handheld Dynamometry (HHD)(12 months)
  • Change from baseline in Maximal Inspiratory Pressure (MIP)(12 months)
  • Change from baseline in motor Functional Independence Measure (motor FIM)(12 months)
  • Change from baseline in Fatigue Severity Scale (FSS)(12 months)
  • 2. Change from baseline in Rasch-Built Overall Amyotrophic Lateral Sclerosis Functional Rating (ROADS)(12 months)
  • Change from baseline in Modified Ashworth Scale (MAS)(12 months)
  • 3. Change from baseline in ALS Assessment Questionnaire, 5-item (ALSAQ-5)(12 months)
  • Change from baseline in Slow Vital Capacity (SVC)(12 months)

Study Sites (1)

Loading locations...

Similar Trials